Close the acquisition of CymaBay Therapeutics, Inc
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Feb 2024
- Due
- 31 Mar 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“anticipated to close during the first quarter of 2024, subject to regulatory approvals and other customary closing conditions.”
What we found
Evidence strength A What the grades mean
A May 2024 10-Q says Gilead used Q1 2024 proceeds from selling its debt securities to partially fund the CymaBay acquisition, implying the deal was funded within the quarter. The exact closing date is not stated.
-
A Gilead Sciences, Inc. 10-Q filed 2024-05-08
“During the three months ended March 31, 2024, we sold all of our available-for-sale debt securities and used the proceeds to partially fund our acquisition of CymaBay discussed in Note 6.” ✓ confirmed on the page
Market reaction: the shares moved +0.1% against the S&P 500 over the three sessions around the disclosure (7 May 2024 to 10 May 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of CymaBay Therapeutics, Inc.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to regulatory approvals; other customary closing conditions; minimum tender of a majority of CymaBay shares; expiration or termination of Hart-Scott-Rodino waiting period
- Depends on
- Regulatory, Shareholder, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Gilead Sciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-GILD-005773 · Corrections policy